HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Cardiol Therapeutics (NASDAQ:CRDL) and maintained a $9 price target.
June 07, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Cardiol Therapeutics and maintained a $9 price target.
The reiteration of a Buy rating and the maintenance of a $9 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100